Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
NCT01890694Phase 4Terminated
- Sponsor
- NYU Langone Health
- Start
- Mar 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hyponatremia comparing Placebo with Tolvaptan (2 arms). Primary endpoint: Length of Hospital Stay. Started Mar 2012; status: terminated.
02
Drugs
tolvaptan
03
Conditions
hyponatremia
Beyond the preview
Go deeper on NCT01890694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890694.